MoonLake Immunotherapeutics Limits Data Release on Sonelokimab Phase 2 Results

The company issued a press release citing statistically significant improvements in primary and secondary measures yet omitted absolute response rates, confidence intervals, and subgroup analyses. This pattern matches prior MoonLake announcements where only directional statements were provided until months later. Observational precedent from other IL-17 inhibitors shows that full datasets typically include PASI-90 rates above 60 percent and adverse event frequencies by system organ class.

Regulatory filings and peer-reviewed reports from similar programs indicate that incomplete disclosure correlates with later protocol amendments or revised statistical plans. Investors and clinicians cannot assess durability, placebo-adjusted effect sizes, or imbalance in serious infections without the underlying tables. The STAT analysis correctly flags repeated instances of this approach across MoonLake’s pipeline.

Context from contemporaneous biotech disclosures shows that companies with robust data release full tables within weeks. MoonLake’s choice to withhold leaves open questions about endpoint hierarchy changes or censoring rules. Next steps include expected presentation at a medical meeting within six months or a regulatory briefing that could compel fuller release.

Evidence calibration: This reporting is based on company statements and secondary journalism rather than a completed peer-reviewed RCT. A full dataset publication or FDA briefing document would allow independent verification of efficacy and safety claims.